share_log

Jaguar Health (NASDAQ:JAGX) Receives New Coverage From Analysts at StockNews.com

Jaguar Health (NASDAQ:JAGX) Receives New Coverage From Analysts at StockNews.com

捷豹健康（NASDAQ：JAGX）在 StockNews 上獲得分析師的新報導
Defense World ·  2022/09/25 02:11

Equities researchers at StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX – Get Rating) in a research report issued on Sunday. The firm set a "hold" rating on the biotechnology company's stock.

股票研究人員在股票新聞網開始報導 捷豹健康 (納斯達克:JAGX — 獲得評級) 在星期日發布的研究報告中。該公司對生物技術公司的股票設定了「持有」評級。

Jaguar Health Stock Performance

捷豹健康股票表現

Shares of Jaguar Health stock opened at $0.17 on Friday. Jaguar Health has a 12-month low of $0.15 and a 12-month high of $2.66. The company has a market cap of $20.00 million, a price-to-earnings ratio of -0.15 and a beta of 1.65. The company has a current ratio of 1.02, a quick ratio of 0.73 and a debt-to-equity ratio of 8.47. The company's 50-day moving average price is $0.25 and its 200-day moving average price is $0.37.

捷豹健康股票的股票上週五以 0.17 美元開盤。捷豹健康的價格為 12 個月低點 0.15 美元，創下 12 個月高點 2.66 美元。該公司的市值為 20.00 萬美元，價格與收益比為 -0.15，測試版為 1.65。該公司的流動比率為 1.02，快速比率為 0.73，債務與權益比率為 8.47。該公司的 50 天移動平均價為 0.25 美元，其 200 天移動平均價格為 0.37 美元。

Get
取得
Jaguar Health
捷豹健康
alerts:
警報：

Jaguar Health (NASDAQ:JAGX – Get Rating) last announced its quarterly earnings results on Monday, August 22nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. Jaguar Health had a negative net margin of 652.35% and a negative return on equity of 486.62%. The firm had revenue of $2.92 million for the quarter. On average, equities analysts expect that Jaguar Health will post -0.67 earnings per share for the current fiscal year.

捷豹健康（NASDAQ：JAGX-獲取評級）上次宣布其季度收益業績於 8 月 22 日星期一。該生物技術公司報告了本季度每股收益（0.12 美元），頂部分析師的共識估計為（0.22 美元）0.10 美元。捷豹健康的負淨利潤率為 652.35％，而負資產回報率為 486.62％。該公司本季度的收入為 2.92 萬美元。平均而言，股票分析師預計，捷豹健康將在本財政年度每股盈利 -0.67。

Institutional Inflows and Outflows

機構流入和流出

Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in shares of Jaguar Health in the first quarter worth approximately $1,079,000. Virtu Financial LLC increased its position in shares of Jaguar Health by 76.1% in the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company's stock worth $162,000 after purchasing an additional 99,073 shares during the last quarter. Millennium Management LLC increased its position in shares of Jaguar Health by 152.3% in the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company's stock worth $157,000 after purchasing an additional 321,795 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Jaguar Health by 507.3% in the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company's stock worth $120,000 after purchasing an additional 141,796 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Jaguar Health by 153.3% in the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 33,148 shares during the last quarter. 7.40% of the stock is currently owned by institutional investors.
機構投資者最近修改了股票的持有量。文藝復興科技有限責任公司買了捷豹健康股份有限公司在第一季度的新位置，價值約為 1,079,000 美元。Virtu 金融有限責任公司在第一季度增加了 76.1％ 的捷豹健康股份的地位。維圖金融有限責任公司現在擁有該生物技術公司股票的 229,270 股，價值 162,000 美元，在上一季度額外購買了 99,073 股。千禧管理有限責任公司在第二季度增加了 152.3％ 在捷豹健康的股份中的地位。千禧管理有限責任公司現在擁有該生物技術公司股票的 533,153 股價值 $157,000 在上一個季度購買了 321,795 股股票之後。紐約梅隆銀行在第一季度增加了其在捷豹健康股份的地位 507.3％。紐約梅隆銀行現在擁有該生物技術公司的 169,749 股股票，價值 12 萬美元，在上一季度額外購買了 141,796 股股票。最後，高盛集團在第一季度增加了其在捷豹健康股份的地位 153.3％。高盛集團在上一季度額外購買 33,148 股股票後，現在擁有該生物技術公司的 54,770 股股票，價值 39,000 美元。7.40％ 的股票目前由機構投資者擁有。

Jaguar Health Company Profile

捷豹健康公司簡介

(Get Rating)

(取得評分)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Jaguar Health, Inc 是一家商業舞台製藥公司，致力於為胃腸道不適的人和動物開發處方藥，特別是慢性和使人衰弱的腹瀉。該公司通過兩個部門運營，人類健康和動物健康。它市場 Mytesi 用於抗逆轉錄病毒治療艾滋病毒/艾滋病成人非感染性腹瀉的症狀緩解。

See Also

另請參閱

  • Get a free copy of the StockNews.com research report on Jaguar Health (JAGX)
  • Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • 2 Semiconductor Stocks To Watch For Reversals
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • 免費獲取有關捷豹健康（JAGX）的研究報告
  • 華爾街對 Datadog 的熱情會導致巨大收益嗎？
  • 市場節拍：評論中的一周 9/19 — 9 月 23 日
  • 為什麼特斯拉股票保持彈性？
  • 2 個半導體股票需要注意反轉
  • 好市多的收益後價格疲軟是買入的好時機嗎？

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.

接收捷豹健康日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收捷豹健康和相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論